JAGX Jan 2024 3.500 call
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 3.50 |
| Expire Date | 2024-01-19 |
| Day's Range | 0.1000 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 48 |
- ACCESSWIRE
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it has entered into a consulting agreement with Andrew Mulberg, M.D. to enhance the company's regulatory expertise. Dr. Mulberg was formerly Deputy Director for six years in the Division of Gastroenterology and Inborn Errors Products at the U.S.
- ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 19, 2023, the Company granted 7,500 restricted stock units (RSUs) to New Employee 1 and 7,500 RSUs to New Employee 2. (These RSU figures reflect grants made prior to the Jaguar reverse stock split that became effective January 23, 2023. Following this reverse stock split, each grant totals 100 RSUs).
- ACCESSWIRE
Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the Company's focus on rare and orphan disease indications: short bowel syndrome (SBS), microvillus inclusion disease (MVID), and cholera. Rare disease indications are the sole focus of Napo Therapeutics, the corporation established by Jaguar in Italy in 2021, with an initial focus on SBS.
